Ever since Covid-19 vaccines have been in development, policy experts and activists have been concerned about equity in vaccine distribution. Now, it is clear that in our haste to get "shots in arms," we are leaving behind many people who are most at risk of Covid-19 infection and death. More
Ever since the initial press release from Pfizer came out, the medical community has been waiting for more detailed results to better analyze the vaccine's effectiveness and safety. Here's what the briefing document shows. More
When we call unproven treatments "cures," we not only put patients at risk of harm, we create a framework in which evidence is no longer valued. Kelsey Chalmers and Judith Garber explore how this perspective could impact the "less is more" movement, and how we need to reframe the issue to build a coalition for change. More
Misinformation about Covid-19 spreads as quickly as the virus, through social media and even from government officials. Let's examine some popular myths about Covid-19 and see if there is any truth to these claims. More
Did Trump receive the "best care possible"? Or was he overtreated? More
From drugs to masks to financial assistance, the US government has distributed Covid-19 resources in a way that exacerbates health inequities. How can we make sure that when a vaccine is ready for distribution, that it goes to those who need it most? More
The FDA's about-face on emergency approval of convalescent plasma raises questions about the level of evidence we need for Covid-19 treatments, and the role of politics in these decisions. More
State budgets have been squeezed over the past decade due in large part to the rising cost of health care, and Covid-19 is only making it worse. What can we do about this problem? More
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
Watch the video of Shannon Brownlee and Jeanne Lenzer discussing pandemic misinformation in a Future Tense conversation. More